Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V L Serebruany

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Thrombosis and Haemostasis|March 9, 2011
Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verifiedV L Serebruany
Thrombosis and Haemostasis|December 22, 2009
The TRITON versus PLATO trials: differences beyond platelet inhibitionV L Serebruany
The American Journal of Cardiology|April 4, 1998
Soluble vascular cell adhesion molecule-1 and E-selectin in patients with acute myocardial infarction treated with thrombolytic agentsP A Gurbel, V L Serebruany
Kardiologiia|October 4, 2013
[The differences between the guidelines of the European Society of Cardiology and the American College of Cardiology/ American Heart Association for oral P2Y12 inhibitor therapy in the management of patients with acute coronary syndromes]V L Serebruany, I V Pershukov
Thrombosis and Haemostasis|May 13, 2014
Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics"V L Serebruany, S D Fortmann
Arteriosclerosis, Thrombosis, and Vascular Biology|January 15, 1999
Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarctionV L Serebruany, P A Gurbel
International Journal of Clinical Practice|February 23, 2007
Dyspnoea after antiplatelet agents: the AZD6140 controversyV L Serebruany, J Stebbing, D Atar
The American Journal of Cardiology|May 11, 1999
Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failureC M O'Connor, P A Gurbel, V L Serebruany
Journal of Thrombosis and Thrombolysis|August 18, 2000
Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study groupP A Gurbel, D J Kereiakes, V L Serebruany
Life Sciences|October 26, 1999
Effects of a novel Mac-1 inhibitor, NPC 15669, on hemostatic parameters during preconditioned myocardial infarctionV L Serebruany, V V Yurovsky, P A Gurbel
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Thrombosis and Haemostasis|March 9, 2011
Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verifiedV L Serebruany
Thrombosis and Haemostasis|December 22, 2009
The TRITON versus PLATO trials: differences beyond platelet inhibitionV L Serebruany
The American Journal of Cardiology|April 4, 1998
Soluble vascular cell adhesion molecule-1 and E-selectin in patients with acute myocardial infarction treated with thrombolytic agentsP A Gurbel, V L Serebruany
Kardiologiia|October 4, 2013
[The differences between the guidelines of the European Society of Cardiology and the American College of Cardiology/ American Heart Association for oral P2Y12 inhibitor therapy in the management of patients with acute coronary syndromes]V L Serebruany, I V Pershukov
Thrombosis and Haemostasis|May 13, 2014
Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics"V L Serebruany, S D Fortmann
Arteriosclerosis, Thrombosis, and Vascular Biology|January 15, 1999
Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarctionV L Serebruany, P A Gurbel
International Journal of Clinical Practice|February 23, 2007
Dyspnoea after antiplatelet agents: the AZD6140 controversyV L Serebruany, J Stebbing, D Atar
The American Journal of Cardiology|May 11, 1999
Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failureC M O'Connor, P A Gurbel, V L Serebruany
Journal of Thrombosis and Thrombolysis|August 18, 2000
Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study groupP A Gurbel, D J Kereiakes, V L Serebruany
Life Sciences|October 26, 1999
Effects of a novel Mac-1 inhibitor, NPC 15669, on hemostatic parameters during preconditioned myocardial infarctionV L Serebruany, V V Yurovsky, P A Gurbel
Pageof 7